18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jun 2019 Status changed from active, no longer recruiting to recruiting.
- 31 Oct 2018 Planned End Date changed from 1 Oct 2020 to 25 Oct 2020.
- 31 Oct 2018 Planned primary completion date changed from 1 Oct 2020 to 25 Oct 2020.